Effects on cognitive functioning after olanzapine-ziprasidone crossover in
recent-onset schizophrenia.
Author(s): Grootens KP, van Veelen NM, Sitskoorn MM, Sabbe BG, Peuskens J, Buitelaar JK,
Verkes RJ, Kahn RS.
Affiliation(s): CWZ General Hospital Nijmegen, Dept. of Psychiatry, Postbus 9015, 6500 GS
Nijmegen, The Netherlands. k.grootens@cwz.nl
Publication date & source: 2010, Eur Neuropsychopharmacol. , 20(12):907-12
INTRODUCTION: To enhance functional outcome in schizophrenia improvement of
cognitive symptoms is crucial.
EXPERIMENTAL PROCEDURES: Using a comprehensive test battery, this follow-up
examines cognitive effects in patients with recent-onset schizophrenia after a
change of medication following insufficient clinical response and intolerance.
RESULTS: After eight weeks cognitive outcomes had not improved in the patients
having switched from olanzapine to ziprasidone (n=11; mean dose 136 mg) nor in
those having switched from ziprasidone to olanzapine (n=10; mean 16 mg), while
the symptoms of patients maintaining olanzapine (n=18; mean 10.9 mg) or
ziprasidone (n=18; mean 88.9 mg) treatment had not improved further.
DISCUSSION: The findings suggest that also in early-stage schizophrenia the
antipsychotics tested affect cognitive symptoms similarly.
|